Currently, due to the exorbitant price of PD-1/PD-L1 antibodies, neither pembrolizumab nor nivolumab present to be cost-effective as second-line treatment for patients with NSCLC in China (Liu et al., 2019; Zhou et al., 2019; Shi et al., 2021). This evidence concerns the gene CD274 and non-small cell lung carcinoma.